Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study.
Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lövig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urosevic N. · 2001
Read Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. by Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lövig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urosevic N. (2001) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2364126.txt.
Introduction
Andreyev and a worldwide group pooled data on ras gene faults in colorectal cancer in 2001. The study, called RASCAL II, gathered records from 42 centres in 21 countries. An earlier round had shown that different faults in the same gene can affect patients differently, a first for a common cancer.
After exclusions, 3,439 patients entered the final analysis. Of 12 possible faults at two spots, codons 12 and 13, of the Kirsten ras gene, only one mattered clearly. Changing glycine to valine at codon 12, found in 8.6% of patients, worsened both survival and time without cancer return. Its harm was strongest in Dukes' C cancers, which had spread to lymph nodes, with a hazard ratio near 1.5 there. The authors said this fault may mark tumors primed for aggressive behaviour.
Catalog record
| CREATOR | Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lövig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urosevic N. |
|---|---|
| YEAR | 2001 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study By H J N Andreyev, A R Norman, D Cunningham, J Oates, B R Dix, B J Iacopetta, J Young, T Walsh, R Ward, N Hawkins, M Beranek, P Jandik Published in: British Journal of Cancer DOI: 10.1054/bjoc.2001.1964 ABSTRACT Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in-colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, which was reanalysed when information on 4268 patients from 42 centres in 21 countries had been entered. After predetermined exclusion criteria were applied, data on 3439 patients were entered into a multivariate analysis. This found that of the 12 possible mutations on codons 12 and 13 of Kirsten ras, only one mutation on codon 12, glycine to valine, found in 8.6% of all patients, had a statistically significant impact on failure-free survival (P = 0.004, HR 1.3) and overall survival (P = 0.008, HR 1.29). This mutation appeared to have a greater impact on outcome in Dukes’ C cancers (failure-free survival, P = 0.008, HR 1.5; overall survival P = 0.02, HR 1.45) than in Dukes’ B tumours (failure-free survival, P = 0.46, HR 1.12; overall survival P = 0.36, HR 1.15). Ki-ras mutations may occur early in the development of pre-cancerous adenomas in the colon and rectum. However, this collaborative study suggests that not only is the presence of a codon 12 glycine to valine mutation important for cancer progression but also that it may predispose to more aggressive biological behaviour in patients with advanced colorectal cancer. © 2001 Cancer Research Campaign http://www.bjcancer.com Presented by the Kirsten ras in-colorectal-cancer collaborative group Kirsten ras mutations in patients with colorectal cancer: the `RASCAL II' study HJN Andreyev1,2 , AR Norman2 , D Cunningham2 , J Oates2 , BR Dix3 , BJ Iacopetta3 , J Young4 , T Walsh5 , R Ward6 , N Hawkins7 , M Beranek8 , P Jandik8 , R Benamouzig9 , E Jullian10 , P Laurent-Puig11 , S Olschwang11 , O Muller12 , I Hoffmann12 , HM Rabes13 , C Zietz13 , C Troungos14 , C Valavanis15 , ST Yuen16 , JWC Ho17 , CT Croke18 , DP O'Donoghue19 , W Giaretti20 , A Rapallo20 , A Russo21 , V Bazan21 , M Tanaka22 , K Omura22 , T Azuma23 , T Ohkusa24 , T Fujimori25 , Y Ono25 , M Pauly26 , C Faber27 , R Glaesener28 , AFPM de Goeij29 , JW Arends29 , SN Andersen30 , T Lovig30 , J Breivik31 , G Gaudernack31 , OPF Clausen30 , P De Angelis30 , GI Meling30 , TO Rognum30 , R Smith32 , H-S Goh32 , A Font33 , R Rosell33 , XF Sun34 , H Zhang35 , J Benhattar36 , L Losi36 , JQ Lee37 , ST Wang38 , PA Clarke39 , S Bell40 , P Quirke40 , VJ Bubb41 , J Piris42 , NR Cruickshank43 , D Morton43 , JC Fox44 , F Al-Mulla45 , N Lees46 , CN Hall46 , D Snary47 , K Wilkinson48 , D Dillon49 , J Costa49 , VE Pricolo50 , SD Finkelstein51 , JS Thebo52 , AJ Senagore52 , SA Halter53 , S Wadler54 , S Malik54 , K Krtolica55 and N Urosevic56 1 Department of Medicine & Therapeutics, Imperial College School of Medicine, Chelsea & Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK, 2 Royal Marsden Hospital, Sutton, UK; 3 University of Western Australia, Nedlands, Australia; 4 Bancroft Centre, Herston, Australia; 5 Queensland University of Technology, Australia; 6 Department of Medical Oncology, St Vincent's Hospital, Sydney, Australia; 7 School of Pathology, University of New South Wales, Sydney, Australia; 8 Charles University Hospital, Hradex Kralove, Czech Republic; 9 Hospital Avicenne, Bobigny; 10 Groupe Hospitalier Cochin-Saint Vincent de Paul, Paris, France, 11 INSERM, Foundation J. Dausset, Paris, France; 12 Max-Planck-Institut fur Molekulare Physiologie, Dortmund, Germany; 13 Institute of Pathology, Ludwig-Maximilians-University of Munich, Germany; 14 Department of Biological Chemistry, University of Athens, Athens, Greece; 15 Department of Biology, Morrill Science Centre, University of Massachusetts, USA; 16 Department of Pathology, Queen Mary Hospital, Hong Kong; 17 Department of Surgery, Queen Mary Hospital, Hong Kong; 18 Royal College of Surgeons, Dublin, Eire; 19 St Vincent's Hospital, Dublin, Eire; 20 Instituto Naziolale per la Ricerca sul Cancro, Genova, Italy; 21 Department of Anatomy, surgery & Oncology, Palermo University, Italy; 22 1st Department of Surgery, School of Medicine, Kanazawa University, Japan; 23 2nd Department of Internal Medicine, Fukui Medical School, Japan; 24 1st Department of Internal Medicine, Tokyo Medical & Dental University, Japan 25 Department of Pathology, Dokkyo University School of Medicine, Tochigi, Japan; 26 RCMS Lab, Fondation `Recherche Cancer et Sang', Luxembourg; 27 Department of Surgery, St-Theresia-Clinics, Luxembourg; 28 Department of Surgery, the Hospital Centre of Luxembourg, Luxembourg; 29 Department of Pathology, Masstricht University, The Netherlands; 30 The National Hospital, Oslo, Norway; 31 The Norwegian Radium Hospital, Oslo, Norway; 32 Molecular Biology Laboratory, Tan Tock Seng Hospital, Singapore; 33 Medical Oncology Service, Hospital Germans Trias I Pujol, Barcelona, Spain; 34 Department of Oncology, University of Linkoping, Sweden; 35 Department of Cell Biology, University of Linkoping; 36 Institut Universitaire de Pathologie, Lausanne, Switzerland; 37 Department of Surgery, National Cheng Kung University, Taiwan; 38 Department of Public Health, National Cheng Kung University, Taiwan; 39 Institute of Cancer Research, Sutton, UK; 40 Molecular Oncology, University of Leeds, UK; 41 Department of Pathology, University Medical School, Edinburgh, UK; 42 Sir Alastair Currie CRC Laboratories, Edinburgh, UK; 43 Queen Elizabeth Hospital, University of Birmingham, UK; 44 Zeneca Diagnostics, Northwich, UK; 45 Beatson Institute for Cancer Research, Glasgow, UK; 46 Department of General Surgery, Wythenshawe Hospital, Manchester, UK; 47 Imperial Cancer Research Fund, London; 48 St Mark's Hospital, Harrow, UK; 49 Yale University School of Medicine, CT, USA; 50 Rhode Island Hospital, Brown University, USA; 51 Department of Pathology, University of Pittsburgh Medical Centre; 52 Ferbuson-Blodget Digestive Disease Institute, Grand Rapids, MI, USA; 53 Vanderbilt University, Nashville, TN, USA; 54 Albert Einstein College of Medicine, Bronx, NY, USA; 55 Institute of Nuclear Sciences `Vinca', Belgrade, Yugoslavia; 56 Military Medical Academy, Belgrade, Yugoslavia Summary Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in- colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, which was reanalysed when information on